Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Autoimmune Disorders

  Free Subscription

Articles published in Kidney Int

Retrieve available abstracts of 183 articles:
HTML format

Single Articles

    September 2021
  1. ZAVALA-MIRANDA MF, Gonzalez-Ibarra SG, Perez-Arias AA, Uribe-Uribe NO, et al
    New onset systemic lupus erythematosus opening as class V lupus nephritis after COVID-19 vaccination.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00869.

  2. ROVIN BH, Furie R, Teng YKO, Contreras G, et al
    A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00862.
    PubMed     Abstract available

  3. HUERTA A, Caballero Bermejo AF, de Villa LF, Sedano R, et al
    Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis.
    Kidney Int. 2021;100:711.

  4. SALHI S, Ribes D, Colombat M, Fortenfant F, et al
    Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy.
    Kidney Int. 2021;100:708-709.

    Fumarate in membranous nephropathy: more questions than answers.
    Kidney Int. 2021;100:707.

    August 2021
  6. GUEGUEN L, Loheac C, Saidani N, Khatchatourian L, et al
    Membranous nephropathy following anti-Covid-19 mRNA vaccination.
    Kidney Int. 2021 Aug 19. pii: S0085-2538(21)00757.

  7. TUSCHEN K, Brasen JH, Schmitz J, Vischedyk M, et al
    Relapse of Class V Lupus Nephritis after Vaccination with COVID-19 mRNA Vaccine.
    Kidney Int. 2021 Aug 2. pii: S0085-2538(21)00738.

  8. PLASSE R, Nee R, Gao S, Olson S, et al
    AKI with Gross Hematuria and IgA Nephropathy after COVID Vaccine.
    Kidney Int. 2021 Aug 2. pii: S0085-2538(21)00739.

    July 2021
  9. DA Y, Goh GH, Khatri P
    A Case of Membranous Nephropathy Following Pfizer-BioNTech mRNA vaccine against Coronavirus 2019.
    Kidney Int. 2021 Jul 29. pii: S0085-2538(21)00735.

  10. HANNA C, Herrera Hernandez LP, Bu L, Kizilbash S, et al
    IgA Nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine.
    Kidney Int. 2021 Jul 5. pii: S0085-2538(21)00666.

  11. RABANT M, Dessaix K, Buob D, Fagniez O, et al
    The Case | Membranous nephropathy after alemtuzumab treatment.
    Kidney Int. 2021;100:249-250.

  12. BERCHTOLD L, Letouze E, Alexander MP, Canaud G, et al
    Corrigendum to Berchtold L, Letouze E, Alexander MP, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int. 2021;99:671-685.
    Kidney Int. 2021;100:243.

    June 2021
  13. KUDOSE S, Friedman P, Albajrami O, D'Agati VD, et al
    Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy.
    Kidney Int. 2021 Jun 17. pii: S0085-2538(21)00598.

  14. PERRIN P, Bassand X, Benotmane I, Bouvier N, et al
    Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy.
    Kidney Int. 2021 Jun 1. pii: S0085-2538(21)00564.

  15. NANGAKU M, Fogo AB
    Does a preclinical randomized controlled trial, pRCT, resolve the gap between animal studies and human trials?
    Kidney Int. 2021;99:1262-1264.
    PubMed     Abstract available

    May 2021
  16. SEKAR A, Campbell R, Tabbara J, Rastogi P, et al
    ANCA glomerulonephritis post Moderna COVID-19 vaccination.
    Kidney Int. 2021 May 31. pii: S0085-2538(21)00555.

  17. TAN HZ, Tan RY, Jun Choo JC, Lim CC, et al
    Is COVID-19 Vaccination unmasking Glomerulonephritis?
    Kidney Int. 2021 May 22. pii: S0085-2538(21)00504.

  18. AYDIN MF, Yildiz A, Oruc A, Sezen M, et al
    Relapse of Primary Membranous Nephropathy after inactivated SARS-CoV-2 Virus Vaccination.
    Kidney Int. 2021 May 13. pii: S0085-2538(21)00494.

  19. KANO T, Suzuki H, Makita Y, Fukao Y, et al
    Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy.
    Kidney Int. 2021 May 4. pii: S0085-2538(21)00467.
    PubMed     Abstract available

  20. CHAPMAN FA, Dhaun N
    STARMEN: progress in membranous nephropathy?
    Kidney Int. 2021;99:1242-1243.

    An impending obituary for the primacy of P values in glomerulonephritis trial results?
    Kidney Int. 2021;99:1241-1242.

  22. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Praga M
    The authors reply.
    Kidney Int. 2021;99:1243.

  23. ANDERS HJ, Lei Y, Rovin BH
    The authors reply.
    Kidney Int. 2021;99:1242.

    April 2021
  24. GUL RAHIM SE, Lin J, Wang JC
    A case of gross hematuria and IgA Nephropathy Flare up following SARS-CoV-2 vaccination.
    Kidney Int. 2021 Apr 28. pii: S0085-2538(21)00465.

  25. WHEELER DC, Toto RD, Stefansson BV, Jongs N, et al
    A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00396.
    PubMed     Abstract available

  26. BARRATT J, Floege J
    SGLT-2 inhibition in IgA nephropathy: the new standard-of-care?
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00385.
    PubMed     Abstract available

  27. LERNER GB, Virmani S, Henderson JM, Francis JM, et al
    A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy.
    Kidney Int. 2021 Apr 12. pii: S0085-2538(21)00377.
    PubMed     Abstract available

  28. SANTORIELLO D, Bomback AS, Kudose S, Batal I, et al
    Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.
    Kidney Int. 2021 Apr 12. pii: S0085-2538(21)00379.
    PubMed     Abstract available

  29. FLOEGE J, Rovin BH
    The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
    Kidney Int. 2021;99:811-813.
    PubMed     Abstract available

  30. DELAFOSSE M, Ponlot E, Esteve E, Ghislain L, et al
    Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
    Kidney Int. 2021;99:1023-1024.

  31. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Praga M
    The authors reply.
    Kidney Int. 2021;99:1024-1025.

    March 2021
  32. ARTINGER K, Kirsch AH, Mooslechner AA, Cooper DJ, et al
    Blockade of tumor necrosis factor superfamily members CD30 and OX40 abrogates disease activity in murine immune-mediated glomerulonephritis.
    Kidney Int. 2021 Mar 27. pii: S0085-2538(21)00345.
    PubMed     Abstract available

    Complement in membranous nephropathy: what we thought we knew and what we really know.
    Kidney Int. 2021 Mar 24. pii: S0085-2538(21)00297.

  34. NEGREA L, Rovin BH
    Gross Hematuria Following Vaccination for SARS-CoV2 in Two Patients with IgA Nephropathy.
    Kidney Int. 2021 Mar 23. pii: S0085-2538(21)00286.

  35. ROBSON KJ, Kitching AR
    Recurrent membranous nephropathy after transplantation: donor antigen and HLA converge in defining risk.
    Kidney Int. 2021;99:545-548.
    PubMed     Abstract available

  36. FARRAH TE, Dhaun N
    Antineutrophil cytoplasm antibody positivity, kidney impairment, and cholesterol embolization.
    Kidney Int. 2021;99:774.

    February 2021
  37. LEI Y, Sehnert B, Voll RE, Jacobs-Cacha C, et al
    A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas(lpr) mice with proliferative lupus nephritis predicts low effect size.
    Kidney Int. 2021 Feb 16. pii: S0085-2538(21)00205.
    PubMed     Abstract available

    Are new treatments for lupus nephritis on the horizon?
    Kidney Int. 2021;99:298-300.

  39. ANDERS HJ, Lei Y, Rovin BH
    Induction and maintenance therapy of lupus nephritis: an obituary.
    Kidney Int. 2021;99:288-291.

    Improving medication adherence in patients with lupus nephritis.
    Kidney Int. 2021;99:285-287.

    January 2021
  41. PAWLUCZYK IZ, Didangelos A, Barbour SJ, Er L, et al
    Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression.
    Kidney Int. 2021 Jan 5. pii: S0085-2538(20)31553.
    PubMed     Abstract available

  42. FLOEGE J, Johnson RJ
    Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?
    Kidney Int. 2021;99:14-16.

  43. RONCO P, Rovin B, Nangaku M, Wyatt C, et al
    Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology.
    Kidney Int. 2021;99:2-4.

  44. KUDOSE S, Santoriello D, Debiec H, Canetta PA, et al
    The clinicopathologic spectrum of segmental membranous glomerulopathy.
    Kidney Int. 2021;99:247-255.
    PubMed     Abstract available

    December 2020
  45. PERKINS GB, Kim J, Coates PT
    Going Rogue: how autoantibodies become pathogenic.
    Kidney Int. 2020 Dec 18. pii: S0085-2538(20)31522.

    November 2020
  46. BARBOUR SJ, Coppo R, Er L, Russo ML, et al
    Updating the International IgA Nephropathy Prediction Tool for use in children.
    Kidney Int. 2020 Nov 18. pii: S0085-2538(20)31385.
    PubMed     Abstract available

  47. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Logt AV, Justino J, et al
    The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
    Kidney Int. 2020 Nov 6. pii: S0085-2538(20)31251.
    PubMed     Abstract available

  48. HAYASHI N, Beck LH Jr
    Moore's law for membranous nephropathy.
    Kidney Int. 2020;98:1081-1084.
    PubMed     Abstract available

  49. TURNER MP, Storey BC, Mittal S, Macanovic J, et al
    Candida crescents in a renal allograft.
    Kidney Int. 2020;98:1356.

    October 2020
  50. CAZA T, Hassen S, Kuperman M, Sharma S, et al
    Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.
    Kidney Int. 2020 Oct 9. pii: S0085-2538(20)31180.
    PubMed     Abstract available

  51. CHEUNG CK, Barratt J
    Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial.
    Kidney Int. 2020;98:836-838.
    PubMed     Abstract available

  52. ODLER B, Flick H, Pollheimer MJ, Goritschan A, et al
    The Case | Glomerulonephritis in a patient with rheumatoid arthritis.
    Kidney Int. 2020;98:1057-1058.

    September 2020
  53. PRENDECKI M, Clarke C, Cairns T, Cook T, et al
    Anti-glomerular basement membrane disease during the COVID-19 pandemic.
    Kidney Int. 2020;98:780-781.

  54. BERCHTOLD L, Letouze E, Alexander MP, Canaud G, et al
    HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients.
    Kidney Int. 2020 Sep 1. pii: S0085-2538(20)30967.
    PubMed     Abstract available

  55. SCHENA FP, Anelli VW, Trotta J, Di Noia T, et al
    Development and testing of an artificial intelligence tool for predicting end stage kidney disease in patients with immunoglobulin A nephropathy.
    Kidney Int. 2020 Sep 1. pii: S0085-2538(20)30969.
    PubMed     Abstract available

    August 2020
  56. CAZA T, Hassen S, Dvanajscak Z, Kuperman M, et al
    NELL1 is a target antigen in malignancy-associated membranous nephropathy.
    Kidney Int. 2020 Aug 20. pii: S0085-2538(20)30956.
    PubMed     Abstract available

    July 2020
  57. IHARA K, Skupien J, Krolewski B, Md Dom ZI, et al
    A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders.
    Kidney Int. 2020 Jul 24. pii: S0085-2538(20)30834.
    PubMed     Abstract available

  58. JO HA, Hyeon JS, Yang SH, Jung Y, et al
    Fumarate modulates phospholipase A2 receptor autoimmunity-induced podocyte injury in membranous nephropathy.
    Kidney Int. 2020 Jul 23. pii: S0085-2538(20)30825.
    PubMed     Abstract available

    June 2020
  59. KURATA Y, Tanaka T, Nangaku M
    The role of hypoxia in the pathogenesis of lupus nephritis.
    Kidney Int. 2020 Jun 26. pii: S0085-2538(20)30702.

  60. ABDIRAMA D, Tesch S, Griessbach AS, von Spee-Mayer C, et al
    Nuclear antigen-reactive CD4(+) T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys.
    Kidney Int. 2020 Jun 24. pii: S0085-2538(20)30704.
    PubMed     Abstract available

  61. SETHI S, Debiec H, Madden B, Vivarelli M, et al
    Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients.
    Kidney Int. 2020 Jun 10. pii: S0085-2538(20)30640.
    PubMed     Abstract available

    May 2020
  62. BARBOUR SJ, Canney M, Coppo R, Zhang H, et al
    Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.
    Kidney Int. 2020 May 25. pii: S0085-2538(20)30544.
    PubMed     Abstract available

  63. RAUEN T, Wied S, Fitzner C, Eitner F, et al
    After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
    Kidney Int. 2020 May 22. pii: S0085-2538(20)30549.
    PubMed     Abstract available

  64. JONES BE, Herrera CA, Agosto-Burgos C, Starmer J, et al
    ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation.
    Kidney Int. 2020 May 21. pii: S0085-2538(20)30538.
    PubMed     Abstract available

    The pathogenesis of human membranous nephropathy: we are (almost) there.
    Kidney Int. 2020;97:849-852.
    PubMed     Abstract available

    April 2020
  66. YANG SR, Hua KF, Chu LJ, Hwu YK, et al
    Xenon blunts NF-kappaB/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice.
    Kidney Int. 2020 Apr 6. pii: S0085-2538(20)30357.
    PubMed     Abstract available

  67. PONTICELLI C, Moroni G
    Discontinuation of therapy in lupus nephritis.
    Kidney Int. 2020;97:806-807.

  68. MALVAR A, Rovin BH
    The authors reply.
    Kidney Int. 2020;97:807.

  69. VAN BOMMEL EJM, Lytvyn Y, Perkins BA, Soleymanlou N, et al
    Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
    Kidney Int. 2020;97:631-635.

    March 2020
  70. SAID SM, Leung N, Alexander MP, Cornell LD, et al
    DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients.
    Kidney Int. 2020 Mar 28. pii: S0085-2538(20)30267.
    PubMed     Abstract available

    February 2020
  71. SCINDIA Y, Wlazlo E, Ghias E, Cechova S, et al
    Modulation of iron homeostasis with hepcidin ameliorates spontaneous murine lupus nephritis.
    Kidney Int. 2020 Feb 17. pii: S0085-2538(20)30139.
    PubMed     Abstract available

  72. TANG J, Liao Z, Meng T, Ning J, et al
    The Case | Glomerulonephritis with prolonged recurrent fever.
    Kidney Int. 2020;97:427-428.

  73. ROVIN BH
    Systemic autoimmune diseases and the kidney.
    Kidney Int. 2020;97:222-225.

    Notch notches lupus.
    Kidney Int. 2020;97:251-253.
    PubMed     Abstract available

  75. SUGAHARA M, Tanaka T, Nangaku M
    Modulating the immune system to delay the clinical onset of type 1 diabetes.
    Kidney Int. 2020;97:248-250.

    January 2020
  76. CRICKX E, Weill JC, Reynaud CA, Mahevas M, et al
    Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives.
    Kidney Int. 2020 Jan 30. pii: S0085-2538(20)30108.
    PubMed     Abstract available

  77. AHMAD SB, Appel GB
    Antigens, antibodies, and membranous nephropathy: a decade of progress.
    Kidney Int. 2020;97:29-31.
    PubMed     Abstract available

  78. JAYNE D, Bajema IM
    "In my beginning is my end": usefulness of repeat kidney biopsies in lupus nephritis.
    Kidney Int. 2020;97:27-29.
    PubMed     Abstract available

  79. SETHI S, Debiec H, Madden B, Charlesworth MC, et al
    Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.
    Kidney Int. 2020;97:163-174.
    PubMed     Abstract available

    November 2019
  80. NASR SH, Larsen CP, Sirac C, Theis JD, et al
    Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone.
    Kidney Int. 2019 Nov 9. pii: S0085-2538(19)31118.
    PubMed     Abstract available

  81. MEYER-SCHWESINGER C, Tomas NM, Dehde S, Seifert L, et al
    A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients.
    Kidney Int. 2019 Nov 9. pii: S0085-2538(19)31115.
    PubMed     Abstract available

  82. LUQUE A, Serrano I, Ripoll E, Malta C, et al
    Noncanonical immunomodulatory activity of complement regulator C4BP(beta-) limits the development of lupus nephritis.
    Kidney Int. 2019 Nov 6. pii: S0085-2538(19)31049.
    PubMed     Abstract available

    October 2019
  83. BREITKOPF DM, Jankowski V, Ohl K, Hermann J, et al
    The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus.
    Kidney Int. 2019 Oct 30. pii: S0085-2538(19)31039.
    PubMed     Abstract available

  84. SMITH JR, Methven S, Stevens KI, MacKinnon B, et al
    Renal risk score performance in a cohort of Scottish patients with ANCA-associated glomerulonephritis.
    Kidney Int. 2019;96:1037.

    September 2019
  85. MAKITA Y, Suzuki H, Kano T, Takahata A, et al
    TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.
    Kidney Int. 2019 Sep 5. pii: S0085-2538(19)30849.
    PubMed     Abstract available

  86. ARAUJO SA, Neves PDMM, Wanderley DC, Reis MAD, et al
    The immunohistological profile of membranous nephropathy associated with chronic Schistosoma mansoni infection reveals a glomerulopathy with primary features.
    Kidney Int. 2019;96:793-794.

    Said the glucose sensor to the insulin pump: can glycemic control be improved in hospitalized ESRD patients with diabetes mellitus?
    Kidney Int. 2019;96:540-542.
    PubMed     Abstract available

    August 2019
  88. MALVAR A, Alberton V, Lococo B, Ferrari M, et al
    Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.
    Kidney Int. 2019 Aug 20. pii: S0085-2538(19)30816.
    PubMed     Abstract available

  89. VAN DE LOGT AE, Fresquet M, Wetzels JF, Brenchley P, et al
    The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.
    Kidney Int. 2019 Aug 12. pii: S0085-2538(19)30807.
    PubMed     Abstract available

  90. FLOEGE J
    A new tool to predict the risk of progression in IgA nephropathy.
    Kidney Int. 2019 Aug 1. pii: S0085-2538(19)30776.

    July 2019
  91. BAGCHI S, Behera V, Agarwal SK
    ACTH (corticotrophin) therapy in resistant primary membranous nephropathy.
    Kidney Int. 2019;96:250-251.

  92. WESTER TREJO MAC, van Daalen EE, Berden AE, Wolterbeek R, et al
    A renal risk score for ANCA-associated glomerulonephritis.
    Kidney Int. 2019;96:245.

    May 2019
  93. GAN PY, Chan A, Ooi JD, Dick J, et al
    Biologicals targeting T helper cell subset differentiating cytokines are effective in the treatment of murine anti-myeloperoxidase glomerulonephritis.
    Kidney Int. 2019 May 27. pii: S0085-2538(19)30531.
    PubMed     Abstract available

  94. KODAMA Y, Hyodo F, Yamato M, Yasukawa K, et al
    Dynamic nuclear polarization magnetic resonance imaging and the oxygen-sensitive paramagnetic agent OX63 provide a noninvasive quantitative evaluation of kidney hypoxia in diabetic mice.
    Kidney Int. 2019 May 24. pii: S0085-2538(19)30515.
    PubMed     Abstract available

  95. OKABAYASHI Y, Nagasaka S, Kanzaki G, Tsuboi N, et al
    Group 1 innate lymphoid cells are involved in the progression of experimental anti-glomerular basement membrane glomerulonephritis and are regulated by peroxisome proliferator-activated receptor alpha.
    Kidney Int. 2019 May 22. pii: S0085-2538(19)30523.
    PubMed     Abstract available

  96. NASR SH, Dasari S, Lieske JC, Benson LM, et al
    Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients.
    Kidney Int. 2019;95:1269-1272.
    PubMed     Abstract available

    Elevated serum concentrations of DNAJB9 in fibrillary glomerulonephritis: another step toward understanding a progressive disease.
    Kidney Int. 2019;95:1025-1026.
    PubMed     Abstract available

    April 2019
  98. NASR SH, Fogo AB
    New developments in the diagnosis of fibrillary glomerulonephritis.
    Kidney Int. 2019 Apr 9. pii: S0085-2538(19)30407.
    PubMed     Abstract available

  99. TRIMARCHI H, Barratt J, Monteiro RC, Feehally J, et al
    IgA nephropathy: "State of the art": a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description.
    Kidney Int. 2019;95:750-756.
    PubMed     Abstract available

  100. BARBOUR S, Djurdjev O, Gill JS, Dong JJ, et al
    A propensity score matched analysis shows no adverse effect of early steroid withdrawal in non-diabetic kidney transplant recipients with and without glomerulonephritis.
    Kidney Int. 2019 Apr 1. pii: S0085-2538(19)30388.
    PubMed     Abstract available

  101. ROVIN BH, Solomons N, Huizinga RB
    The authors reply.
    Kidney Int. 2019;95:992-993.

  102. TRACHTMAN H, Caplan AL
    Data monitoring committees and randomized clinical trials.
    Kidney Int. 2019;95:992.

    March 2019
  103. MYETTE JR, Kano T, Suzuki H, Sloan SE, et al
    A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.
    Kidney Int. 2019 Mar 16. pii: S0085-2538(19)30174.
    PubMed     Abstract available

  104. CANNEY M, Induruwage D, McCandless LC, Reich HN, et al
    Disease-specific incident glomerulonephritis displays geographic clustering in under-serviced rural areas of British Columbia, Canada.
    Kidney Int. 2019 Mar 15. pii: S0085-2538(19)30315.
    PubMed     Abstract available

  105. PUELLES VG, Fleck D, Ortz L, Papadouri S, et al
    Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis.
    Kidney Int. 2019 Mar 15. pii: S0085-2538(19)30318.
    PubMed     Abstract available

  106. ZAGHRINI C, Seitz-Polski B, Justino J, Dolla G, et al
    Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
    Kidney Int. 2019;95:666-679.
    PubMed     Abstract available

  107. NAKAMURA J, Sato Y, Kitai Y, Wajima S, et al
    Myofibroblasts acquire retinoic acid-producing ability during fibroblast-to-myofibroblast transition following kidney injury.
    Kidney Int. 2019;95:526-539.
    PubMed     Abstract available

    February 2019
  108. KOUSIOS A, Duncan N, Tam FWK, Chaidos A, et al
    Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID): diagnostic and treatment challenges for the nephrologist!
    Kidney Int. 2019;95:467-468.

  109. BOBART SA, De Vriese AS, Pawar AS, Zand L, et al
    Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.
    Kidney Int. 2019;95:429-438.
    PubMed     Abstract available

  110. ROVIN BH, Almaani S, Malvar A
    Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.
    Kidney Int. 2019;95:265-267.
    PubMed     Abstract available

  111. WANG L, Chang JH, Buckley AF, Spurney RF, et al
    Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice.
    Kidney Int. 2019;95:321-332.
    PubMed     Abstract available

  112. ROVIN BH, Caster DJ, Cattran DC, Gibson KL, et al
    Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2019;95:281-295.
    PubMed     Abstract available

  113. FLOEGE J, Barbour SJ, Cattran DC, Hogan JJ, et al
    Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2019;95:268-280.
    PubMed     Abstract available

    January 2019
  114. KITAGAWA A, Tsuboi N, Yokoe Y, Katsuno T, et al
    Urinary levels of the leukocyte surface molecule CD11b associate with glomerular inflammation in lupus nephritis.
    Kidney Int. 2019 Jan 26. pii: S0085-2538(18)30826.
    PubMed     Abstract available

  115. WILSON HR, Medjeral-Thomas NR, Gilmore AC, Trivedi P, et al
    Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.
    Kidney Int. 2019 Jan 8. pii: S0085-2538(18)30789.
    PubMed     Abstract available

  116. DAHAN K, Johannet C, Esteve E, Plaisier E, et al
    Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.
    Kidney Int. 2019;95:233-234.

  117. CRAIG JC
    Interpreting trial results-time for confidence and magnitude and not P values please.
    Kidney Int. 2019;95:28-30.
    PubMed     Abstract available

    December 2018
    ANCA Renal Risk Score: is prediction of end-stage renal disease at baseline possible?
    Kidney Int. 2018;94:1045-1047.
    PubMed     Abstract available

    November 2018
  119. KASINATH V, Yilmam OA, Uehara M, Jiang L, et al
    Activation of fibroblastic reticular cells in kidney lymph node during crescentic glomerulonephritis.
    Kidney Int. 2018 Nov 29. pii: S0085-2538(18)30647.
    PubMed     Abstract available

  120. ROVIN BH, Solomons N, Pendergraft WF 3rd, Dooley MA, et al
    A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
    Kidney Int. 2018 Nov 5. pii: S0085-2538(18)30628.
    PubMed     Abstract available

  121. BECK LH JR, Salant DJ
    Deep pockets are not necessarily a good thing in membranous nephropathy: evidence for a modifier allele.
    Kidney Int. 2018;94:855-857.
    PubMed     Abstract available

    October 2018
  122. MULLER MB, Hoppe JM, Bideak A, Lux M, et al
    Exclusive expression of transmembrane TNF aggravates acute glomerulonephritis despite reduced leukocyte infiltration and inflammation.
    Kidney Int. 2018 Oct 30. pii: S0085-2538(18)30594.
    PubMed     Abstract available

  123. BRIX SR, Noriega M, Tennstedt P, Vettorazzi E, et al
    Development and validation of a renal risk score in ANCA-associated glomerulonephritis.
    Kidney Int. 2018 Oct 23. pii: S0085-2538(18)30552.
    PubMed     Abstract available

  124. RAMACHANDRAN R, Yadav AK, Sethi J, Gupta KL, et al
    Antibodies to M-type phospholipase receptor and immunological remission in treatment-resistant and relapsing membranous nephropathy.
    Kidney Int. 2018;94:829-830.

    Repeat kidney biopsy for lupus nephritis: an important step forward.
    Kidney Int. 2018;94:659-661.
    PubMed     Abstract available

  126. VAN DE LOGT AE, Dahan K, Ronco P, Wetzels J, et al
    The authors reply.
    Kidney Int. 2018;94:830.

    August 2018
  127. WANG HY, Cui Z, Xie LJ, Zhang LJ, et al
    HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy.
    Kidney Int. 2018 Aug 26. pii: S0085-2538(18)30441.
    PubMed     Abstract available

    July 2018
  128. DE ROSA M, Azzato F, Toblli JE, De Rosa G, et al
    A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.
    Kidney Int. 2018 Jul 20. pii: S0085-2538(18)30395.
    PubMed     Abstract available

  129. FLOEGE J, Daha MR
    IgA nephropathy: new insights into the role of complement.
    Kidney Int. 2018;94:16-18.
    PubMed     Abstract available

    June 2018
  130. ARKATKAR T, Jacobs HM, Du SW, Li QZ, et al
    TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.
    Kidney Int. 2018 Jun 12. pii: S0085-2538(18)30252.
    PubMed     Abstract available

  131. ROPS ALWMM, Jansen E, van der Schaaf A, Pieterse E, et al
    Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.
    Kidney Int. 2018;93:1356-1366.
    PubMed     Abstract available

    May 2018
  132. SAHA MK, Julian BA, Novak J, Rizk DV, et al
    Secondary IgA nephropathy.
    Kidney Int. 2018 May 24. pii: S0085-2538(18)30245.
    PubMed     Abstract available

  133. ZHU L, Guo WY, Shi SF, Liu LJ, et al
    Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy.
    Kidney Int. 2018 May 11. pii: S0085-2538(18)30214.
    PubMed     Abstract available

  134. GUMBER R, Cohen JB, Palmer MB, Kobrin SM, et al
    A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.
    Kidney Int. 2018 May 11. pii: S0085-2538(18)30211.
    PubMed     Abstract available

  135. LIM CC, Choo JCJ, Chan CM, Woo KT, et al
    Age-adjusted global glomerulosclerosis in addition to Oxford histological classification of IgA nephropathy.
    Kidney Int. 2018;93:1250.

  136. NADA R, Ramachandran R, Kumar A, Gupta KL, et al
    Tumoral masses in failed kidneys.
    Kidney Int. 2018;93:1253.

  137. DESIDERI S, Onions KL, Qiu Y, Ramnath RD, et al
    A novel assay provides sensitive measurement of physiologically relevant changes in albumin permeability in isolated human and rodent glomeruli.
    Kidney Int. 2018;93:1086-1097.
    PubMed     Abstract available

  138. HOMMOS MS, Zeng C, Liu Z, Troost JP, et al
    Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment.
    Kidney Int. 2018;93:1175-1182.
    PubMed     Abstract available

    April 2018
  139. SAID SM, Cosio FG, Valeri AM, Leung N, et al
    Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.
    Kidney Int. 2018 Apr 28. pii: S0085-2538(18)30175.
    PubMed     Abstract available

  140. ELLER K, Rosenkranz AR
    Atypical chemokine receptors-"chemokine PACMANs" as new therapeutic targets in glomerulonephritis.
    Kidney Int. 2018;93:774-775.
    PubMed     Abstract available

  141. Fu J, Wang Z, Lee K, et al. Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney Int. 2018;93:416-429.
    Kidney Int. 2018;93:1018.

  142. VAN DE LOGT AE, Dahan K, Rousseau A, van der Molen R, et al
    Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
    Kidney Int. 2018;93:1016-1017.

    March 2018
  143. FLOEGE J
    IgA nephropathy: toward more specific diagnosis (and rescue of snails).
    Kidney Int. 2018;93:542-544.
    PubMed     Abstract available

  144. LAUSECKER F, Tian X, Inoue K, Wang Z, et al
    Vinculin is required to maintain glomerular barrier integrity.
    Kidney Int. 2018;93:643-655.
    PubMed     Abstract available

    February 2018
  145. HONG Q, Zhang L, Das B, Li Z, et al
    Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury.
    Kidney Int. 2018 Feb 22. pii: S0085-2538(18)30033.
    PubMed     Abstract available

  146. BAJEMA IM, Wilhelmus S, Alpers CE, Bruijn JA, et al
    Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.
    Kidney Int. 2018 Feb 16. pii: S0085-2538(17)30859.
    PubMed     Abstract available

  147. MOON JS, Mun CH, Kim JH, Cho JY, et al
    Intranuclear delivery of the transcription modulation domain of Tbet-improved lupus nephritis in (NZB/NZW) F1 lupus-prone mice.
    Kidney Int. 2018 Feb 3. pii: S0085-2538(17)30853.
    PubMed     Abstract available

    January 2018
  148. BIDEAK A, Blaut A, Hoppe JM, Muller MB, et al
    The atypical chemokine receptor 2 limits renal inflammation and fibrosis in murine progressive immune complex glomerulonephritis.
    Kidney Int. 2018 Jan 22. pii: S0085-2538(17)30829.
    PubMed     Abstract available

  149. SUZUKI H, Yasutake J, Makita Y, Tanbo Y, et al
    IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
    Kidney Int. 2018 Jan 9. pii: S0085-2538(17)30799.
    PubMed     Abstract available

  150. BOMBACK AS, Santoriello D, Avasare RS, Regunathan-Shenk R, et al
    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
    Kidney Int. 2018 Jan 6. pii: S0085-2538(17)30802.
    PubMed     Abstract available

  151. STOKES MB, D'Agati VD
    Full-house glomerular deposits: beware the sheep in wolf's clothing.
    Kidney Int. 2018;93:18-20.
    PubMed     Abstract available

  152. RIJNINK EC, Teng YKO, Kraaij T, Dekkers OM, et al
    Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits.
    Kidney Int. 2018;93:214-220.
    PubMed     Abstract available

  153. LIANG G, Song L, Chen Z, Qian Y, et al
    Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism.
    Kidney Int. 2018;93:95-109.
    PubMed     Abstract available

    December 2017
  154. EYMAEL J, Sharma S, Loeven MA, Wetzels JF, et al
    CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis.
    Kidney Int. 2017 Dec 21. pii: S0085-2538(17)30770.
    PubMed     Abstract available

  155. DICK J, Gan PY, Ford SL, Odobasic D, et al
    C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis.
    Kidney Int. 2017 Dec 11. pii: S0085-2538(17)30768.
    PubMed     Abstract available

    November 2017
  156. AMANN K
    Do ANCAs make the difference in lupus nephritis?
    Kidney Int. 2017;92:1048-1050.
    PubMed     Abstract available

  157. FU J, Wang Z, Lee K, Wei C, et al
    Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis.
    Kidney Int. 2017 Nov 1. pii: S0085-2538(17)30671.
    PubMed     Abstract available

    October 2017
  158. THURMAN JM, Laskowski J
    Complement factor H-related proteins in IgA nephropathy-sometimes a gentle nudge does the trick.
    Kidney Int. 2017;92:790-793.
    PubMed     Abstract available

    September 2017
  159. SINGH G, Bhardwaj S, Singh L, Sinha A, et al
    Proliferative glomerulonephritis with monotypic IgA-kappa deposits in a 10-year-old.
    Kidney Int. 2017;92:765-766.

    August 2017
    Recurrence of glomerulonephritis: an underestimated and unmet medical need.
    Kidney Int. 2017;92:294-296.
    PubMed     Abstract available

  161. FLOEGE J
    Mucosal corticosteroid therapy of IgA nephropathy.
    Kidney Int. 2017;92:278-280.
    PubMed     Abstract available

    July 2017
  162. DAI Y, Chen A, Liu R, Gu L, et al
    Retinoic acid improves nephrotoxic serum-induced glomerulonephritis through activation of podocyte retinoic acid receptor alpha.
    Kidney Int. 2017 Jul 27. pii: S0085-2538(17)30321.
    PubMed     Abstract available

  163. BROCKLEBANK V, Johnson S, Sheerin TP, Marks SD, et al
    Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
    Kidney Int. 2017 Jul 24. pii: S0085-2538(17)30323.
    PubMed     Abstract available

  164. TURNER-STOKES T, Wilson HR, Morreale M, Nunes A, et al
    Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy.
    Kidney Int. 2017 Jul 24. pii: S0085-2538(17)30324.
    PubMed     Abstract available

  165. GALSGAARD J, Persson F, Hansen TW, Jorsal A, et al
    Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Kidney Int. 2017 Jul 13. pii: S0085-2538(17)30310.
    PubMed     Abstract available

  166. BOJIC M, Kozakowski N, Becede M, Kerschbaumer A, et al
    The Case | Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus.
    Kidney Int. 2017;92:271-272.

    June 2017
  167. MEDJERAL-THOMAS NR, Lomax-Browne HJ, Beckwith H, Willicombe M, et al
    Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy.
    Kidney Int. 2017 Jun 30. pii: S0085-2538(17)30256.
    PubMed     Abstract available

  168. TORTAJADA A, Gutierrez E, Goicoechea de Jorge E, Anter J, et al
    Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy.
    Kidney Int. 2017 Jun 18. pii: S0085-2538(17)30254.
    PubMed     Abstract available

  169. ALLEN PJ, Chadban SJ, Craig JC, Lim WH, et al
    Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes.
    Kidney Int. 2017 Jun 7. pii: S0085-2538(17)30208.
    PubMed     Abstract available

  170. VAN LAECKE S, Van Biesen W
    Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?
    Kidney Int. 2017;91:1271-1274.
    PubMed     Abstract available

    May 2017
  171. GUL A, Harford A, Zager P
    Mendelian randomization to establish the causality of uric acid with diabetic nephropathy in type 1 diabetics.
    Kidney Int. 2017;91:1005-1007.
    PubMed     Abstract available

    April 2017
  172. YAMANOUCHI M, Skupien J, Niewczas MA, Smiles AM, et al
    Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.
    Kidney Int. 2017 Apr 7. pii: S0085-2538(17)30112.
    PubMed     Abstract available

    March 2017
  173. KROLEWSKI AS, Skupien J, Rossing P, Warram JH, et al
    Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes.
    Kidney Int. 2017 Mar 30. pii: S0085-2538(17)30081.
    PubMed     Abstract available

  174. TRIMARCHI H, Barratt J, Cattran DC, Cook HT, et al
    Oxford Classification of IgA nephropathy 2016-the role of crescentic lesions: an update from the IgA Nephropathy Classification Working Group.
    Kidney Int. 2017 Mar 21. pii: S0085-2538(17)30101.
    PubMed     Abstract available

  175. ROSENZWAJG M, Languille E, Debiec H, Hygino J, et al
    B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.
    Kidney Int. 2017 Mar 15. pii: S0085-2538(17)30039.
    PubMed     Abstract available

  176. VIGNON M, Cohen C, Faguer S, Noel LH, et al
    The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits.
    Kidney Int. 2017;91:720-728.
    PubMed     Abstract available

  177. HE X, Cheng R, Park K, Benyajati S, et al
    Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway.
    Kidney Int. 2017;91:642-657.
    PubMed     Abstract available

    February 2017
  178. AHOLA AJ, Sandholm N, Forsblom C, Harjutsalo V, et al
    The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes.
    Kidney Int. 2017 Feb 21. pii: S0085-2538(16)30757.
    PubMed     Abstract available

    January 2017
  179. KLEMIS V, Ghura H, Federico G, Wurfel C, et al
    Circulating fibronectin contributes to mesangial expansion in a murine model of type 1 diabetes.
    Kidney Int. 2017 Jan 31. pii: S0085-2538(16)30706.
    PubMed     Abstract available

    December 2016
  180. KIM CS, Bae EH, Ma SK, Kim SW, et al
    The Case | Seizure, ophthalmoplegia, and amnesia in a peritoneal dialysis patient.
    Kidney Int. 2016;90:1389-1390.

    November 2016
  181. YOU H, Gao T, Raup-Konsavage WM, Cooper TK, et al
    Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
    Kidney Int. 2016 Nov 30. pii: S0085-2538(16)30598.
    PubMed     Abstract available

    July 2016
  182. TAKASHIMA S, Fujita H, Fujishima H, Shimizu T, et al
    Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Kidney Int. 2016 Jul 27. pii: S0085-2538(16)30273.
    PubMed     Abstract available

    April 2016
  183. KLESSENS CQ, Woutman TD, Veraar KA, Zandbergen M, et al
    An autopsy study suggests that diabetic nephropathy is underdiagnosed.
    Kidney Int. 2016 Apr 9. pii: S0085-2538(16)00313.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.